
Grifols, S.A. GRFS
$ 7.41
1.37%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
680 M |
Market Cap[1] |
$ 5.04 B |
EBITDA (LTM) |
$ 1.97 B |
P/E (LTM) |
27.79 |
P/S (LTM) |
0.49 |
EPS (LTM) |
0.29 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 76.31 | 0.69 % | $ 5.66 B | Nasdaq Global Select Market | ||
|
Kodiak Sciences
KOD
|
$ 93.81 | 0.32 % | $ 4.99 B | Nasdaq Global Market,SPB | ||
|
Karyopharm Therapeutics
KPTI
|
$ 0.67 | 1.51 % | $ 7.33 K | Nasdaq Global Select Market | ||
|
Keros Therapeutics
KROS
|
$ 11.52 | 1.41 % | $ 429 M | Nasdaq Global Select Market | ||
|
Krystal Biotech
KRYS
|
$ 334.85 | 3.9 % | $ 9.69 B | Nasdaq Global Market,SPB | ||
|
Kura Oncology
KURA
|
$ 10.62 | 0.09 % | $ 931 M | Nasdaq Global Select Market | ||
|
Kymera Therapeutics
KYMR
|
$ 109.85 | 2.29 % | $ 9.28 B | Nasdaq Global Market | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 9.35 | 0.86 % | $ 143 M | Nasdaq Global Select Market | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.93 | 2.73 % | $ 214 M | NYSE American | ||
|
Legend Biotech Corporation
LEGN
|
$ 18.77 | 1.1 % | $ 6.92 B | Nasdaq Global Select Market | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 306.77 | 1.26 % | $ 5.93 B | Nasdaq Global Select Market,SPB | ||
|
Longeveron
LGVN
|
$ 2.51 | 0.39 % | $ 44.1 B | Nasdaq Global Select Market | ||
|
Eli Lilly and Company
LLY
|
$ 1 143.12 | 0.02 % | $ 1.03 T | NYSE,SPB | ||
|
Lipocine
LPCN
|
$ 2.07 | 0.98 % | $ 11.3 M | Nasdaq Global Select Market | ||
|
Liquidia Corporation
LQDA
|
$ 27.64 | 2.32 % | $ 2.38 B | Nasdaq Capital Market | ||
|
Larimar Therapeutics
LRMR
|
$ 2.86 | 1.75 % | $ 238 M | Nasdaq Global Market | ||
|
Lantern Pharma
LTRN
|
$ 0.94 | 9.3 % | $ 10.2 M | Nasdaq Global Select Market | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.74 | 0.82 % | $ 632 M | Nasdaq Global Select Market | ||
|
Mustang Bio
MBIO
|
$ 0.46 | 1.16 % | $ 2.26 M | Nasdaq Global Market | ||
|
Moleculin Biotech
MBRX
|
$ 0.48 | 0.42 % | $ 569 K | Nasdaq Global Select Market | ||
|
Seres Therapeutics
MCRB
|
$ 2.85 | 0.34 % | $ 25.2 M | Nasdaq Global Select Market | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 493.62 | 0.1 % | $ 11.1 B | Nasdaq Global Select Market,SPB | ||
|
MediWound Ltd.
MDWD
|
$ 13.51 | 0.22 % | $ 368 M | Nasdaq Global Select Market | ||
|
Mesoblast Limited
MESO
|
$ 14.22 | 0.99 % | $ 17.2 B | Nasdaq Global Select Market | ||
|
MacroGenics
MGNX
|
$ 3.77 | 5.31 % | $ 238 M | Nasdaq Global Select Market | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 10.92 | 1.2 % | $ 878 M | Nasdaq Global Select Market | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 81.43 | 0.07 % | $ 4.09 B | Nasdaq Global Select Market | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.78 | 0.25 % | $ 82.9 M | Nasdaq Global Select Market | ||
|
MannKind Corporation
MNKD
|
$ 3.82 | 0.53 % | $ 1.17 B | Nasdaq Global Market | ||
|
MediciNova
MNOV
|
$ 1.76 | 0.28 % | $ 86.4 M | Nasdaq Global Market | ||
|
Monopar Therapeutics
MNPR
|
$ 78.29 | 0.41 % | $ 580 M | Nasdaq Global Select Market | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.39 | 2.16 % | $ 311 M | Nasdaq Global Select Market | ||
|
Merck & Co.
MRK
|
$ 139.54 | 0.34 % | $ 349 B | NYSE,SPB | ||
|
Marker Therapeutics
MRKR
|
$ 1.06 | 0.95 % | $ 16.2 M | Nasdaq Global Market | ||
|
Moderna
MRNA
|
$ 203.21 | 6.95 % | $ 79 B | Nasdaq Global Select Market,SPB | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 8.52 | 7.85 % | $ 1.23 B | Nasdaq Global Select Market | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 2.82 | 6.82 % | $ 15.4 M | NYSE American | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Neurocrine Biosciences
NBIX
|
$ 144.21 | 0.72 % | $ 14.3 B | Nasdaq Global Select Market,SPB | ||
|
Nanobiotix S.A.
NBTX
|
$ 25.1 | 0.16 % | $ 1.2 T | Nasdaq Global Select Market | ||
|
NuCana plc
NCNA
|
$ 1.06 | 2.75 % | $ 11.9 B | Nasdaq Global Select Market | ||
|
Minerva Neurosciences
NERV
|
$ 3.32 | 1.22 % | $ 28.1 M | Nasdaq Global Market | ||
|
Nektar Therapeutics
NKTR
|
$ 42.22 | 2.2 % | $ 712 M | Nasdaq Global Select Market,SPB | ||
|
Nkarta
NKTX
|
$ 2.53 | 0.59 % | $ 187 M | Nasdaq Global Select Market | ||
|
NanoViricides
NNVC
|
$ 1.45 | 13.28 % | $ 29.3 M | NYSE American | ||
|
Nurix Therapeutics
NRIX
|
$ 22.88 | 0.09 % | $ 1.98 B | Nasdaq Global Select Market,SPB | ||
|
Nuvation Bio
NUVB
|
$ 4.95 | 1.07 % | $ 1.69 B | NYSE | ||
|
Novavax
NVAX
|
$ 12.56 | 20.08 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
Novo Nordisk A/S
NVO
|
$ 37.54 | 0.59 % | $ 167 B | NYSE | ||
|
Novartis AG
NVS
|
$ 140.93 | 0.01 % | $ 273 B | NYSE |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.